ORPHA:658590
Eyelid sebaceous carcinoma
Publications
243
70.6th percentile
Trials
1
Interventional, condition-specific
Researchers
794
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0021588
- UMLS:C4525405
- NCIT:C134831
Additional Mondo synonyms (5)
carcinoma of sebaceous gland of eyelid · eyelid SGC · eyelid sebaceous gland carcinoma · sebaceous gland carcinoma of the eyelid · sebaceous gland of eyelid carcinoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
243 matched papers (128 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
1 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
243
243 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
243 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
128 in the last 10 years · medium confidence · 70.6th percentile (publications denominator)
Phrase hits: 243 · MeSH hits: 0
Who's working on it?
794
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Sen S14 papers · 2024
Division of Ocular Pathology, RP Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Papers in Europe PMC - 02Esmaeli B12 papers · 2025
Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Papers in Europe PMC - 03Shields CL9 papers · 2026
Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Papers in Europe PMC - 04Jayaraj P8 papers · 2024
Department of Ocular Pathology, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Papers in Europe PMC - 05Jia R8 papers · 2025
Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China.. Electronic address: renbingjia@sjtu.edu.cn.
Papers in Europe PMC - 06Kaliki S8 papers · 2026
Operation Eyesight Universal Institute for Eye Cancer, L V Prasad Eye Institute, Hyderabad, India. kalikiswathi@yahoo.com.
Papers in Europe PMC - 07Kashyap S8 papers · 2024
Department of Ocular Pathology, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Papers in Europe PMC - 08Pushker N8 papers · 2024
Ophthalmoplasty Service, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Papers in Europe PMC - 09Bakhshi S7 papers · 2024
Department of Medical Oncology, IRCH, All India Institute of Medical Sciences, New Delhi, India.
Papers in Europe PMC - 10Fan X7 papers · 2023
Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
1
interventional trials for this specific condition
1 interventional trial matched this specific condition name; none in our sample are currently recruiting.
Data as of 27 July 2026
1 interventional trial — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 76.8th percentile).
medium confidence · 76.8th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
1 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Eyelid sebaceous carcinoma" OR "carcinoma of sebaceous gland of eyelid" OR "carcinoma of the sebaceous gland of the eyelid" OR "eyelid SGC" OR "eyelid sebaceous gland carcinoma" OR "sebaceous gland carcinoma of the eyelid" OR "sebaceous gland carcinoma of eyelid" OR "sebaceous gland of eyelid carcinoma" OR "sebaceous gland of the eyelid carcinoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Eyelid sebaceous carcinoma" OR "carcinoma of sebaceous gland of eyelid" OR "carcinoma of the sebaceous gland of the eyelid" OR "eyelid SGC" OR "eyelid sebaceous gland carcinoma" OR "sebaceous gland carcinoma of the eyelid" OR "sebaceous gland carcinoma of eyelid" OR "sebaceous gland of eyelid carcinoma" OR "sebaceous gland of the eyelid carcinoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 1 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (243) is high for prevalence class "<1 / 1 000 000" — confidence capped at medium
Ingested 2026-07-27T20:03:37.102Z